Jobe Alan H
Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, Ohio, USA.
Biol Neonate. 2006;89(4):298-302. doi: 10.1159/000092866. Epub 2006 Jun 1.
Surfactant is now standard of care for infants with respiratory distress syndrome. Surfactant treatments are effective because of complex metabolic interactions between surfactant and the preterm lung. The large treatment dose functions as substrate; it is taken up by the preterm lung and is reprocessed and secreted with improved function. The components of the treatment surfactant remain in the preterm lung for days. If lung injury is avoided, then surfactant inhibition is minimized. Prenatal corticosteroids complement surfactant to further enhance lung function. The magic of surfactant therapy results from the multiple interactions between surfactant and the preterm lung.
表面活性剂现已成为呼吸窘迫综合征婴儿的标准治疗方法。表面活性剂治疗之所以有效，是因为表面活性剂与早产肺之间存在复杂的代谢相互作用。大剂量的治疗性表面活性剂起到底物的作用；它被早产肺吸收，经过重新加工并以功能得到改善的形式分泌出来。治疗性表面活性剂的成分会在早产肺中留存数天。如果能避免肺损伤，那么表面活性剂的抑制作用就会降至最低。产前使用皮质类固醇可补充表面活性剂，进一步增强肺功能。表面活性剂疗法的神奇效果源于表面活性剂与早产肺之间的多重相互作用。
